PTGX insider trading
NasdaqGM HealthcareProtagonist Therapeutics, Inc — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Protagonist Therapeutics, Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Company website: www.protagonist-inc.com
PTGX insider activity at a glance
FilingIQ has scored 384 insider transactions for PTGX since Aug 16, 2016. The most recent filing in our index is dated May 12, 2026.
Across the full history, 13 open-market purchases
and 116 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on PTGX insider trades is 64.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest PTGX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading PTGX
Frequently asked
- How many insider trades does FilingIQ track for PTGX?
- FilingIQ tracks 384 Form 4 insider transactions for PTGX (Protagonist Therapeutics, Inc), covering filings from Aug 16, 2016 onwards. 37 of those were filed in the last 90 days.
- Are PTGX insiders net buyers or net sellers?
- Across the full Form 4 history for PTGX, 13 transactions (3%) were open-market purchases and 116 (30%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does PTGX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is PTGX in?
- Protagonist Therapeutics, Inc (PTGX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5.49B.
Methodology & sources
Every PTGX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.